FOOTHILL RANCH, Calif., Could 16, 2022 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the world-wide chief in dental lasers, these days introduced that it has been given notice from the Nasdaq Stock Sector LLC (Nasdaq) on May perhaps 13, 2022 informing BIOLASE that it has regained compliance with the minimal bid value prerequisite below Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for ongoing listing on The Nasdaq Cash Marketplace. For that reason, BIOLASE is now in compliance with all relevant listing requirements and its frequent inventory will keep on to be stated on The Nasdaq Money Market place.

BIOLASE was earlier notified by Nasdaq on May 24, 2021 that it was not in compliance with the least bid cost rule because its popular inventory failed to meet up with the closing bid selling price of $1.00 or more for 30 consecutive enterprise days. To get back compliance with the Rule, the Company was necessary to maintain a bare minimum closing bid rate of $1.00 or extra for at least 10 consecutive buying and selling times. The necessity was fulfilled on Might 12, 2022, the tenth consecutive investing working day when the closing bid rate of the Firm’s typical inventory was about $1.00.

On April 28, 2022, BIOLASE announced that it had effected a 1-for-25 reverse stock break up that became productive at 11:59 p.m. ET that similar working day, and that BIOLASE frequent stock would start off investing on a split-modified foundation at the opening of the marketplace on April 29, 2022. The goal of the reverse inventory break up was to raise the for every share trading price tag of the Corporation frequent inventory to proceed its listing on the Nasdaq Funds Industry.


BIOLASE is a medical system enterprise that develops, manufactures, markets, and sells laser techniques in dentistry and drugs. BIOLASE’s items advance the practice of dentistry and drugs for clients and health care experts. BIOLASE’s proprietary laser goods integrate somewhere around 301 patented and 32 patent-pending systems designed to give biologically and clinically exceptional general performance with considerably less ache and quicker recovery times. BIOLASE’s modern products and solutions offer slicing-edge engineering at competitive rates to produce exceptional effects for dentists and patients. BIOLASE’s principal goods are revolutionary dental laser programs that accomplish a wide vary of dental processes, including cosmetic and advanced surgical purposes. BIOLASE has marketed above 43,300 laser systems to day in over 80 nations all over the globe. Laser products and solutions below growth address BIOLASE’s main dental current market and other adjacent professional medical and purchaser purposes.

For updates and facts on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at, Facebook at, Twitter at, Instagram at, and LinkedIn at

BIOLASE®, Waterlase® and Waterlase iPlus® are registered emblems of BIOLASE, Inc.

Cautionary Statement Relating to Ahead-Searching Statements

This press launch includes ahead-wanting statements, as that term is outlined in the Private Litigation Reform Act of 1995, that include substantial risks and uncertainties, which include statements with regards to the predicted roll out of new go-to-market place sales techniques, the Organizations attempts to accomplish its intention of becoming EBITDA beneficial. Ahead-hunting statements can be discovered through the use of text this sort of as anticipates,” “expects,” “intends,” “plans,” “thinks,” “seeks,” “estimates,” “may perhaps,” “will,” “must,” and variants of these phrases or similar expressions. Viewers are cautioned not to area undue reliance on these forward-on the lookout statements, which replicate BIOLASEs present anticipations and speak only as of the date of this launch. Genuine final results may perhaps vary materially from BIOLASEs current expectations based on a number of components. These components incorporate, among the some others, adverse improvements in general financial and market place ailments, competitive factors such as but not limited to pricing pressures and new product introductions, uncertainty of purchaser acceptance of new product or service choices and industry modifications, threats associated with managing the expansion of the small business, and those people other challenges and uncertainties that are described, from time-to-time, in the “Hazard Factors” portion of BIOLASE’s once-a-year studies submitted on Variety 10-K with the Securities and Trade Fee. Besides as necessary by regulation, BIOLASE does not undertake any duty to revise or update any ahead-looking statements.

Source BIOLASE, Inc.